The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Systemic Lupus ErythematosusLupus Nephritis
Interventions
BIOLOGICAL

Human umbilical cord mesenchymal stem cells

Human umbilical cord mesenchymal stem cells (1 × 10 \^6 cells / kg body weight, suspended in 30ml saline), intravenous drip once.

DRUG

Interleukin-2

IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.

Trial Locations (1)

210008

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER